The Next Generation of Neurological Care Starts Here

Parkinson’s Disease (PD) is a neurological disorder with an onset in mid to late adult life that is primarily characterized by impaired motor function and loss of control associated with the death of neurons and the appearance of toxic oligomeric protein fibrils being agglomerates of alpha synuclein fibrils. When the oligomeric fibrils increase in length, they form linkages to make roman-key shaped structures in the form of planar sheets termed alpha synuclein plaques. Such plaques are stabilized by physiological salts such as sodium and potassium.

Alzheimer’s Disease (AD) is a neurocognitive disorder with an onset in mid to late adult life that is primarily characterized by impaired mental function and loss of memory associated with the death of neurons and the appearance of toxic protein fibrils containing largely glutamate oligomeric fibrils. When these fibrils reach lengths greater than about 36 amino acid residues, they form linkages to make curved planar sheets with hairpin structures termed beta plaques.

Pharmzandia Corporation research has now led to breakthrough pharmaceutical materials that we believe are reasonable candidate treatments for these debilitating diseases. Clinical trials are now being considered in early collaborative planning and risk management. Medical institutions and universities are encouraged to join our vision for improved therapy results for the greater good.

If you are interested in doing follow-up medical work with us, we will welcome your expertise and hope you can share more about your organization with us.